Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/38953
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Engelen, Matthias M | - |
dc.contributor.author | Van Thillo, Quentin | - |
dc.contributor.author | Betrains, Albrecht | - |
dc.contributor.author | Gyselinck, Iwein | - |
dc.contributor.author | Martens, Caroline P | - |
dc.contributor.author | Spalart, Valérie | - |
dc.contributor.author | Ockerman, Anna | - |
dc.contributor.author | Devooght, Caroline | - |
dc.contributor.author | Wauters, Joost | - |
dc.contributor.author | Gunst, Jan | - |
dc.contributor.author | Wouters, Carine | - |
dc.contributor.author | Vandenbriele, Christophe | - |
dc.contributor.author | Rex, Steffen | - |
dc.contributor.author | Liesenborghs, Laurens | - |
dc.contributor.author | Wilmer, Alexander | - |
dc.contributor.author | Meersseman, Philippe | - |
dc.contributor.author | Van den Berghe, Greet | - |
dc.contributor.author | Dauwe, Dieter | - |
dc.contributor.author | Belmans, Ann | - |
dc.contributor.author | THOMEER, Michiel | - |
dc.contributor.author | Fivez, Tom | - |
dc.contributor.author | MESOTTEN, Dieter | - |
dc.contributor.author | RUTTENS, David | - |
dc.contributor.author | Heytens, Luc | - |
dc.contributor.author | Dapper, Ilse | - |
dc.contributor.author | Tuyls, Sebastiaan | - |
dc.contributor.author | De Tavernier, Brecht | - |
dc.contributor.author | Verhamme, Peter | - |
dc.contributor.author | Vanassche, Thomas | - |
dc.date.accessioned | 2022-12-02T09:28:29Z | - |
dc.date.available | 2022-12-02T09:28:29Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2022-11-03T19:14:43Z | - |
dc.identifier.citation | Research and Practice in Thrombosis and Haemostasis, 6 (7) , p. e12826 | - |
dc.identifier.uri | http://hdl.handle.net/1942/38953 | - |
dc.description.abstract | Background: Thromboinflammation plays a central role in severe COVID-19. The kallikrein pathway activates both inflammatory pathways and contact-mediated coagulation. We investigated if modulation of the thromboinflammatory response improves outcomes in hospitalized COVID-19 patients. Methods: In this multicenter open-label randomized clinical trial (EudraCT 2020-001739-28), patients hospitalized with COVID-19 were 1:2 randomized to receive standard of care (SOC) or SOC plus study intervention. The intervention consisted of aprotinin (2,000,000 IE IV four times daily) combined with low molecular weight heparin (LMWH; SC 50 IU/kg twice daily on the ward, 75 IU/kg twice daily in intensive care). Additionally, patients with predefined hyperinflammation received the interleukin-1 receptor antagonist anakinra (100 mg IV four times daily). The primary outcome was time to a sustained 2-point improvement on the 7-point World Health Organization ordinal scale for clinical status, or discharge. Findings: Between 24 June 2020 and 1 February 2021, 105 patients were randomized, and 102 patients were included in the full analysis set (intervention N = 67 vs. SOC N = 35). Twenty-five patients from the intervention group (37%) received anakinra. The intervention did not affect the primary outcome (HR 0.77 [CI 0.50-1.19], p = 0.24) or mortality (intervention n = 3 [4.6%] vs. SOC n = 2 [5.7%], HR 0.82 [CI 0.14-4.94], p = 0.83). There was one treatment-related adverse event in the intervention group (hematuria, 1.49%). There was one thrombotic event in the intervention group (1.49%) and one in the SOC group (2.86%), but no major bleeding. Conclusions: In hospitalized COVID-19 patients, modulation of thromboinflammation with high-dose aprotinin and LMWH with or without anakinra did not improve outcome in patients with moderate to severe COVID-19. | - |
dc.language.iso | en | - |
dc.publisher | - | |
dc.subject.other | COVID‐19 | - |
dc.subject.other | anakinra | - |
dc.subject.other | aprotinin | - |
dc.subject.other | heparin | - |
dc.subject.other | inflammation | - |
dc.subject.other | low‐molecular‐weight | - |
dc.subject.other | thrombosis | - |
dc.title | Modulation of thromboinflammation in hospitalized COVID-19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn-Antico study | - |
dc.type | Journal Contribution | - |
dc.identifier.issue | 7 | - |
dc.identifier.spage | e12826 | - |
dc.identifier.volume | 6 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | 111 RIVER ST, HOBOKEN 07030-5774, NJ USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1002/rth2.12826 | - |
dc.identifier.pmid | 36324831 | - |
dc.identifier.isi | 000875879800001 | - |
local.provider.type | PubMed | - |
local.uhasselt.international | no | - |
item.contributor | Engelen, Matthias M | - |
item.contributor | Van Thillo, Quentin | - |
item.contributor | Betrains, Albrecht | - |
item.contributor | Gyselinck, Iwein | - |
item.contributor | Martens, Caroline P | - |
item.contributor | Spalart, Valérie | - |
item.contributor | Ockerman, Anna | - |
item.contributor | Devooght, Caroline | - |
item.contributor | Wauters, Joost | - |
item.contributor | Gunst, Jan | - |
item.contributor | Wouters, Carine | - |
item.contributor | Vandenbriele, Christophe | - |
item.contributor | Rex, Steffen | - |
item.contributor | Liesenborghs, Laurens | - |
item.contributor | Wilmer, Alexander | - |
item.contributor | Meersseman, Philippe | - |
item.contributor | Van den Berghe, Greet | - |
item.contributor | Dauwe, Dieter | - |
item.contributor | Belmans, Ann | - |
item.contributor | THOMEER, Michiel | - |
item.contributor | Fivez, Tom | - |
item.contributor | MESOTTEN, Dieter | - |
item.contributor | RUTTENS, David | - |
item.contributor | Heytens, Luc | - |
item.contributor | Dapper, Ilse | - |
item.contributor | Tuyls, Sebastiaan | - |
item.contributor | De Tavernier, Brecht | - |
item.contributor | Verhamme, Peter | - |
item.contributor | Vanassche, Thomas | - |
item.fullcitation | Engelen, Matthias M; Van Thillo, Quentin; Betrains, Albrecht; Gyselinck, Iwein; Martens, Caroline P; Spalart, Valérie; Ockerman, Anna; Devooght, Caroline; Wauters, Joost; Gunst, Jan; Wouters, Carine; Vandenbriele, Christophe; Rex, Steffen; Liesenborghs, Laurens; Wilmer, Alexander; Meersseman, Philippe; Van den Berghe, Greet; Dauwe, Dieter; Belmans, Ann; THOMEER, Michiel; Fivez, Tom; MESOTTEN, Dieter; RUTTENS, David; Heytens, Luc; Dapper, Ilse; Tuyls, Sebastiaan; De Tavernier, Brecht; Verhamme, Peter & Vanassche, Thomas (2022) Modulation of thromboinflammation in hospitalized COVID-19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn-Antico study. In: Research and Practice in Thrombosis and Haemostasis, 6 (7) , p. e12826. | - |
item.accessRights | Open Access | - |
item.fulltext | With Fulltext | - |
crisitem.journal.eissn | 2475-0379 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Research and Practice in Thrombosis and Haemostasis - 2022 - Engelen - Modulation of thromboinflammation in hospitalized.pdf | Published version | 1.7 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.